The MaxCyte’s ExPERT™ platform is making waves in overcoming lost runs during scale-up. Nitin Kulkarni, PhD, a Senior Field Applications Scientist at MaxCyte, shares valuable insights on enhancing cell viability and recovery. With MaxCyte's Flow Electroporation technology®, Nitin and the team addressed cell viability challenges, ensuring a seamless transition to patient dosing. MaxCyte’s innovative approach empowers researchers and clinicians to navigate the complexities of cell therapy. From discovery to commercialization, the ExPERT™ platform offers best-in-class electroporation technology, scalability, and ongoing support from a global team of experts. If you’re passionate about #CellTherapy and #Innovation, check out our groundbreaking work! https://lnkd.in/gMHFspka
MaxCyte, Inc.
Biotechnology
Rockville, Maryland 8,309 followers
Let's Build Better Cells Together
About us
At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients’ lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today’s processes to innovate tomorrow’s solutions. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: three instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health. Our Vision: Together, we maximize the potential of cells to improve lives. Our Mission: We build trust with our customers, and together we leverage best-in-class technology and expertise to solve the toughest challenges in cell engineering, bringing therapies to patients. Our Core Values: - We value and respect each other, our partners, and patients - We remain undaunted in our commitment to relieving the burden of disease - We dig deep, working together to understand the problem, and always find a way - We stay curious and connected, and never get complacent - We approach each person, each situation with compassion and transparency - We take pride in the excellence of our technology and the expertise we deliver
- Website
-
http://www.maxcyte.com
External link for MaxCyte, Inc.
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 1999
- Specialties
- Vaccine Development, Protein Production, Transfection, Cell Therapy, Gene Therapy, Cancer, Immunotherapy, Electroporation, MyExpertPlatform, Tcell, NKcell, Bispecifics, Gene Editing, Cancer Research, Immuno-oncology, Stem Cell, CARMA, Cell Engineering, Biotechnology, Life Sciences, and Innovation
Locations
-
Primary
Get directions
9713 Key West Ave
Suite 400
Rockville, Maryland 20850, US
Employees at MaxCyte, Inc.
Updates
-
Congratulations to StapleBio Inc. Yousuke Katsuda for adding MaxCyte's technology to their labs with their new ExPERT ATx electroporation instrument! This drug discovery startup with a research facility in Okinawa, Japan, develops "Staple Nucleic Acid" molecules that suppress gene expression by targeting repetitive guanine sequences. We are excited to work with the team, and look forward to supporting their work along the way. 沖縄に研究所がある創薬ベンチャー・StapleBio様 (@YousukeKatsuda様) にMaxCyteのエレクトロポレーション機器ExPERT ATxを採用していただきました！グアニンの繰り返し配列を手繰り寄せて遺伝子の発現を抑制する"Staple核酸"技術の研究開発を応援しております
-
-
Advance your induced pluripotent stem cell research with our recently launched eBook, Exploring Electroporation 3: iPSCs. Discover how MaxCyte's flow electroporation technology is advancing iPSC research. #iPSCs #electroporation https://bit.ly/45LGde7
-
-
Get to know Jill Mayer, our Senior Vice President of Human Resources, and the vibrant culture she helps to foster here at MaxCyte. Our team is our biggest asset and we are growing! Check out our job openings and join our expanding family today. https://bit.ly/4cNqtd2
-
Watch the virtual breakout session featuring James Brady, PhD, Senior Vice President of Technical Applications at MaxCyte, as he presents on how electroporation is an effective tool in engineering scalable cell therapies. Learn about the power of #CRISPR technology in precisely modifying genes for therapeutic purposes and more. https://bit.ly/4cshbmL
-
Listen to Lauren Unsworth, Research Associate II at MaxCyte as she presents her poster presentation on non-viral cell engineering of peripheral blood natural killer cells using a GMP-compliant, scalable electroporation platform. Check out this resource and more in our latest newsletter. https://bit.ly/4eJSt2M
-
"It is increasingly necessary for developers to explore alternative, non-viral approaches that can enhance the safety and efficacy of these groundbreaking therapies." James Brady, MaxCyte Senior Vice President, Technical Applications and Customer Support, highlights the risks associated with viral vectors in cell and gene therapy (CGT). With safety concerns like oncogenesis and high manufacturing costs, the need for safer alternatives is clear. #Electroporation stands out as a promising non-viral method, offering lower safety risks, greater payload flexibility, and reduced production complexities. This technique is already making waves, as seen with Vertex's FDA-approved CRISPR therapy, Casgevy. Embracing electroporation could revolutionize CGT development. Read more in Genetic Engineering & Biotechnology News: https://lnkd.in/e8jcCEdm
-
We are excited to announce the release our newest Cell Therapy eBook Series : Exploring Electroporation 3: Induced Pluripotent Stem Cells. This edition of the eBook series discusses the tremendous potential of iPSCs to transform human health, and their unique ability to differentiate into any cell type is important to disease modeling and both personalized and allogeneic regenerative medicine. Download now to learn more. https://bit.ly/45LGde7
-
-
#CRISPR-based therapies have countless applications for medical conditions, from rare genetic diseases and cancer to even common concerns like high cholesterol. “Great advances have been made toward enabling targeted knock-in of genes following CRISPR editing. Improved knock-in efficiency stems from advances in DNA template design along with optimization of delivery technologies and cell-handling protocols.” In a recent Biocompare article, James Brady, MaxCyte Senior Vice President, explains how CRISPR editing can improve gene knock-in efficiency, the critical players and activities necessary for successful editing, and the transfection of CRISPR reagents. Learn more: https://bit.ly/3VCxndY
CRISPR Transfection Offers Endless Possibilities with the Right Resources
biocompare.com
-
We are proud to announce our collaboration with Porton Advanced │ Cell & Gene Therapy CDMO/CRO as they introduce the MaxCyte cGMP-grade Expert GTx Flow Electroporation instrument into their cell therapy platform. This marks our first- ever cell therapy CDMO in China to possess a clinical-grade flow electroporation system. We look forward to working with Porton Advanced and warmly welcome them to the MaxCyte family. https://lnkd.in/gk3vMjQR
🌟 Exciting Cell Therapy News from Porton Advanced! 🌟 Porton Advanced is thrilled to announce the addition of the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to our cell therapy platform. As the first cell therapy CDMO in China to adopt this advanced system, we are enhancing our capabilities in high-efficiency, scalable transfection from research to clinical production. This allows us to provide advanced process development and production services for cell therapy projects at various stages, including IIT, IND application, and clinical trials. By introducing the MaxCyte GTx technology, Porton Advanced has further strengthened its capabilities in non-viral electroporation while empowering and accelerating the translation of gene and cell therapy drugs from the lab to the clinic and, ultimately, to the market. Join us in driving innovation in cell therapy! 🔬 Learn more here: https://lnkd.in/dXDnceiy #IND #IIT #CellTherapy #PortonAdvanced #MaxCyte #GTxFlow #GeneTherapy #mRNA #Lentivirus #Plasmid #GMP #CMC